Page last updated: 2024-12-11

n-stearoylsphingomyelin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-(N-steroylsphingosyl)-1-phosphocholine: RN & structure given in first source; RN not in Chemline 12/87 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-stearoylsphingosine-1-phosphocholine : A sphingomyelin d18:1 in which the ceramide N-acyl group is specified as stearoyl (octadecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

sphingomyelin 18:0 : A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 18 with 0 double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6453725
CHEMBL ID1609656
CHEBI ID83358
SCHEMBL ID14889266
MeSH IDM0103076

Synonyms (49)

Synonym
LMSP03010001
n-(octadecanoyl)-sphing-4-enine-1-phosphocholine
c18 sphingomyelin
sm(d18:1/18:0)
NCGC00161363-01
2,3-sppc
n-stearoyl-d-erythro-sphingosylphosphorylcholine
58909-84-5
BML3-D05
[(e,2s,3r)-3-hydroxy-2-(octadecanoylamino)octadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
sphingomyelin 18:0
05ug6280ni ,
3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium, 4-hydroxy-7-(1-hydroxy-2-hexadecenyl)-n,n,n-trimethyl-9-oxo-, hydroxide, inner salt, 4-oxide, (r-(r*,s*-(e)))-
stearoylsphingomyelin
n-stearoylsphingosine-phosphorylcholine
2,3-(n-steroylsphingosyl)-1-phosphocholine
unii-05ug6280ni
3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium, 4-hydroxy-7-((1r,2e)-1-hydroxy-2-hexadecenyl)-n,n,n-trimethyl-9-oxo-, inner salt, 4-oxide, (7s)-
n-stearoylsphingomyelin
sphingomyelins n-stearoylsphingomyelin [mi]
n-stearoylsphingosine-1-phosphocholine
3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium, 4-hydroxy-7-(1-hydroxy-2-hexadecenyl)-n,n,n-trimethyl-9-oxo-, inner salt, 4-oxide, (r-(r*,s*-(e)))-
n-octadecanoylsphing-4-enine-1-phosphocholine
stearoyl sphingomyelin
(2s,3r,4e)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate
n-stearoylsphing-4-enine-1-phosphocholine
sphingomyelin (d18:1/18:0)
(2s,3r,4e)-3-hydroxy-2-(stearoylamino)octadec-4-en-1-yl 2-(trimethylammonio)ethyl phosphate
CHEBI:83358 ,
n-octadecanoylsphingosine-1-phosphocholine
SCHEMBL14889266
CHEMBL1609656
AS-60769
(2-{[(2s,3r,4e)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl phosphonato]oxy}ethyl)trimethylazanium
sm d36:1
18:0 sm (d18:1/18:0), n-stearoyl-d-erythro-sphingosylphosphorylcholine, powder
brain sm, sphingomyelin (brain, porcine), powder
ethanaminium, 2-[[hydroxy[[(2r,3s,4e)-3-hydroxy-2-[(1-oxooctadecyl)amino]-4-octadecen-1-yl]oxy]phosphinyl]oxy]-n,n,n-trimethyl-, inner salt, rel-
134731-80-9
Q27156784
sphingomyelin from bovine brain
n-octadecanoylsphingosylphosphorylcholine
n-acyl-4-sphingenyl-1-o-phosphorylcholine;n-acyl-d-sphingosine-1-phosphocholine
AKOS037645436
CS-0621186
HY-148388
DTXSID501313528
sphingomyelin (bovine spinal cord)
ethanaminium,2-[[hydroxy[[(2r,3s,4e)-3-hydroxy-2-[(1-oxooctadecyl)amino]-4-octadecen-1-yl]oxy]phosphinyl]oxy]-n,n,n-trimethyl-,innersalt,rel-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sphingomyelin 36:1A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 36 with 1 double bond.
sphingomyelin d18:1Any sphingomyelin having sphingosine as the sphingoid component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Sphingolipid metabolism (integrated pathway)1167
Sphingolipid metabolism: integrated pathway163
Sphingolipid pathway315
Sphingolipids metabolism pathway063

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's3 (30.00)18.2507
2000's2 (20.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]